Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanjivani Paranterals's ROE % for the quarter that ended in Mar. 2026 was 4.55%. Sanjivani Paranterals's PB Ratio for the quarter that ended in Mar. 2026 was 3.38.
Sanjivani Paranterals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 1.35%.
Sanjivani Paranterals ROE % Adjusted to Book Value Related Terms
Sanjivani Paranterals ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Sanjivani Paranterals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanjivani Paranterals ROE % Adjusted to Book Value Chart
BOM:531569 vs ZTS: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sanjivani Paranterals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanjivani Paranterals ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanjivani Paranterals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Sanjivani Paranterals's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 1.35% mean?
Sanjivani Paranterals (BOM:531569) has a ROE % Adjusted to Book Value of 1.35% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sanjivani Paranterals and its competitors.
Is Sanjivani Paranterals' ROE % Adjusted to Book Value too high?
Sanjivani Paranterals' current ROE % Adjusted to Book Value is 1.35%. Overall, Sanjivani Paranterals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanjivani Paranterals' ROE % Adjusted to Book Value compare to ZTS?
Sanjivani Paranterals' ROE % Adjusted to Book Value of 1.35% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sanjivani Paranterals and its competitors. Sanjivani Paranterals's current ROE % Adjusted to Book Value is 1.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanjivani Paranterals stock overvalued right now?
Based on GuruFocus' analysis, Sanjivani Paranterals (BOM:531569) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹226.27, compared to a current price of ₹160.65 — trading 29% below its estimated fair value. The current ROE % Adjusted to Book Value is 1.35%. Sanjivani Paranterals' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Sanjivani Paranterals (BOM:531569), the current ROE % Adjusted to Book Value is 1.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanjivani Paranterals (BOM:531569) Overvalued in 2026?
Based on GuruFocus' analysis, Sanjivani Paranterals stock appears to be undervalued.
The current stock price of ₹160.65 is trading 29% below its estimated GF Value™ of ₹226.27.
GuruFocus considers Sanjivani Paranterals to be Modestly Undervalued.
Key valuation signals for BOM:531569:
ROE % Adjusted to Book Value: 1.35%
GF Value™: ₹226.27 vs. price of ₹160.65 (29% below fair value)
No single metric tells the full story. See the BOM:531569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanjivani Paranterals Ltd is a pharmaceutical company principally engaged in providing pharmaceutical products and services. The company's main product range includes oral solids and small-volume parenteral and sterile powder formulations. The products offered by the company are anti-biotic, anti-emetic, anti-tuberculosis, anti-diabetic, anti-malarial, anti-fungal, calcium and vitamin, multivitamin, sedative, cardiovascular, anti-gout, and others. The company also provides Liquid Injection, Dry powder Injection, Capsules, Drops, and others. The firm sells its products in India and internationally.
73GF Score
Get the complete analysis for BOM:531569
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531569 has been successfully added to your 
